Multicenter comparison of cefoxitin versus cefazolin for prevention of infectious morbidity after nonelective cesarean section.
A randomized double-blind placebo-controlled comparison of prophylactic cefoxitin, an antibiotic with good activity against anaerobic bacteria, with cefazolin, an agent effective predominantly against aerobes, was undertaken in 354 women who underwent nonelective cesarean section (124 receiving cefoxitin, 119 cefazolin, and 111 placebo). Among the placebo group, 24.3% developed genital tract-related infection, in comparison to 5.6% of the cefoxitin patients and 6.7% of the cefazolin patients (P less than 0.001). Standard febrile morbidity, fever index, and duration of postoperative hospital stay were also significantly less in the antibiotic prophylactic groups. For patients with febrile morbidity, the mean fever index was less in the cefoxitin group (24.8 degree-hours) than that in the cefazolin group (42.7 degree-hours), and this difference approached statistical significance (P less than 0.1, greater than 0.05). Postoperative hospital stay longer than 1 week for infectious morbidity occurred in 26% of cefoxitin patients, a significantly lower incidence compared to the 66% rate for patients who received cefazolin, and the 57% incidence for patients in the placebo group (P less than 0.05).
D000328:Adult; D001424:Bacterial Infections / Q000517:prevention & control*; D002437:Cefazolin / Q000627:therapeutic use*; D002440:Cefoxitin / Q000627:therapeutic use*; D002585:Cesarean Section; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005334:Fever / Q000209:etiology; D005831:Genital Diseases, Female / Q000209:etiology; D006801:Humans; D007231:Infant, Newborn; D007902:Length of Stay; D011183:Postoperative Complications / Q000517:prevention & control; D011247:Pregnancy; D011292:Premedication; D011897:Random Allocation
D002440:Cefoxitin; D002437:Cefazolin